Abstract
There are three methods for making chronic myelogenous leukemia (CML) mouse models: xenotransplantation of primary Ph-positive CML cells into immunodeficient mice, BCR/ABL-expressing transgenic mice, and BCR/ABL retroviral bone marrow transduction and transplantation. These animal models have provided us with important new insights into the molecular pathophysiology of CML and answered directly many questions regarding this disease. To date, The model mice using the BCR/ABL retroviral bone marrow transduction and transplantation method has provided the most valuable knowledge compared with the other two methods. After a long history of failure, however, recent studies have reported successful establishment of making the CMLphenotype in transgenic mice. The transgenic CML mouse model now appears to be more accurate, informative and advantageous model for studying CML. This article reviews the history of BCR/ABL-expressing CML mouse models and the recent findings in the transgenic mice with the CML-phenotype.
Keywords: chronic myelogenous, cml-phenotype, bcr, abl
Current Genomics
Title: Transgenic Mouse Models of BCR/ABL-Positive Chronic Myelogenous Leukemia: A Review
Volume: 6 Issue: 2
Author(s): Koiti Inokuchi
Affiliation:
Keywords: chronic myelogenous, cml-phenotype, bcr, abl
Abstract: There are three methods for making chronic myelogenous leukemia (CML) mouse models: xenotransplantation of primary Ph-positive CML cells into immunodeficient mice, BCR/ABL-expressing transgenic mice, and BCR/ABL retroviral bone marrow transduction and transplantation. These animal models have provided us with important new insights into the molecular pathophysiology of CML and answered directly many questions regarding this disease. To date, The model mice using the BCR/ABL retroviral bone marrow transduction and transplantation method has provided the most valuable knowledge compared with the other two methods. After a long history of failure, however, recent studies have reported successful establishment of making the CMLphenotype in transgenic mice. The transgenic CML mouse model now appears to be more accurate, informative and advantageous model for studying CML. This article reviews the history of BCR/ABL-expressing CML mouse models and the recent findings in the transgenic mice with the CML-phenotype.
Export Options
About this article
Cite this article as:
Inokuchi Koiti, Transgenic Mouse Models of BCR/ABL-Positive Chronic Myelogenous Leukemia: A Review, Current Genomics 2005; 6 (2) . https://dx.doi.org/10.2174/1389202053642267
DOI https://dx.doi.org/10.2174/1389202053642267 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Deep learning in Single Cell Analysis
The field of biology is undergoing a revolution in our ability to study individual cells at the molecular level, and to integrate data from multiple sources and modalities. This has been made possible by advances in technologies for single-cell sequencing, multi-omics profiling, spatial transcriptomics, and high-throughput imaging, as well as ...read more
New insights on Pediatric Tumors and Associated Cancer Predisposition Syndromes
Because of the broad spectrum of children cancer susceptibility, the diagnosis of cancer risk syndromes in children is rarely used in direct cancer treatment. The field of pediatric cancer genetics and genomics will only continue to expand as a result of increasing use of genetic testing tools. It's possible that ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting Vesicle Trafficking: An Important Approach to Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Patents and the Development on Polymer based Nanomaterial (PAMAM Dendrimer) for Biomedical Applications
Recent Patents on Biomedical Engineering (Discontinued) Production of Retroviral Vectors: Review
Current Gene Therapy Adverse Effects of Tacrolimus in Renal Transplant Patients from Living Donors
Current Drug Safety Nanoparticle Drug Delivery Systems: Recent Patents and Applications in Nanomedicine
Recent Patents on Nanomedicine A Technological Update of Molecular Diagnostics for Infectious Diseases
Infectious Disorders - Drug Targets Electrically-Assisted Nucleic Acids Delivery to Tissues In Vivo: Where Do We Stand?
Current Pharmaceutical Design The Small Heat Shock Protein HspB8: Role in Nervous System Physiology and Pathology
CNS & Neurological Disorders - Drug Targets Editorial [Hot topic: Developing New Anti-Cancer Drugs (Guest Editor: Ricardo De Souza Pereira)]
Recent Patents on Anti-Cancer Drug Discovery Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets Synthesis, Molecular Targets, and Antitumor Activities of Substituted Tetrahydro-1- Oxopyrano[4,3-b][1]Benzopyrans and Nanogels for Drug Delivery
Anti-Cancer Agents in Medicinal Chemistry Effectiveness of Two Novel Anionic and Cationic Platinum Complexes in the Treatment of Osteosarcoma
Anti-Cancer Agents in Medicinal Chemistry Antibody-Drug Conjugate Targets
Current Cancer Drug Targets Role of the Endosomal ESCRT Machinery in HIV-1 Vpu-Induced Down- Regulation of BST2/Tetherin
Current HIV Research Mass Spectrometric Imaging of the Nervous System
Current Pharmaceutical Design Bioengineering RNA Silencing Across the Life Kingdoms
Recent Patents on Biotechnology Focal Adhesion Kinase as a Therapeutic Target of Bortezomib
Anti-Cancer Agents in Medicinal Chemistry New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies
Current Medicinal Chemistry Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer
Current Drug Targets